Onconic Therapeutics' Nesuparib Receives Orphan Drug Designation from US FDA for Small Cell Lung Cancer
Sequential orphan drug designations for the same candidate
from pancreatic and gastric cancer to small cell lung cancer
Onconic Therapeutics announced on the 24th that its next-generation dual-target synthetic lethal anticancer drug candidate, Nesuparib, has received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) as a treatment for small cell lung cancer (SCLC). Nesuparib had previously received orphan drug designation for pancreatic cancer in 2021 and for gastric cancer in 2025, and has now added small cell lung cancer to the list.
Small cell lung cancer is a hard-to-treat malignancy characterized by rapid proliferation, early metastasis, and a high recurrence rate, and it is an area where treatment options are limited once the disease relapses after first-line therapy. Nesuparib is a dual-mechanism synthetic lethal anticancer agent that simultaneously inhibits PARP, an enzyme protein, and tankyrase (TNKS). It is designed to concurrently target inhibition of DNA damage repair and blockade of tumor growth and adaptive signaling.
Small cell lung cancer is a tumor type that exhibits high genomic instability and dependence on replication stress due to loss of the TP53 and RB1 genes. Therapeutic strategies targeting the DNA damage response are therefore considered to have strong rationale. New approaches such as combination regimens with immune checkpoint inhibitors and DLL3-targeted therapies are currently being explored, but treatment options that can induce a durable response after relapse remain limited.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Onconic Therapeutics is conducting a phase 2 clinical trial of Nesuparib in pancreatic cancer, a phase 2 clinical trial in ovarian cancer in combination with Vegzelma, an investigator-initiated phase 2 clinical trial in endometrial cancer in combination with Keytruda, and a phase 1b/2 clinical trial in gastric cancer. A company representative said, "We plan to continue expanding the indications of Nesuparib, focusing on tumor types with high dependence on replication stress and DNA damage response."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.